cetuximab,atezolizumab,bevacizumab
roche,eli lilly,merck
['beva', 'cetuximab', 'bevacizumab', 'headandneck', 'atezo']
. will share 3201 trial of chemotherapy plus cetuximab versus chemotherapy plus bevacizumab versus atezolizumab plus bevacizumab following progression on immune checkpoint inhibition in recurrent/metastatic #headandneckcancer #asco22. 
Yale Cancer Center is a collaboration between renowned cancer researchers and physicians @Yale and @SmilowCancer.